How Are CLL Patients Monitored After a Clinical Trial Concludes?
How Are CLL Patients Monitored After a Clinical Trial Concludes? from Patient Empowerment Network on Vimeo.
What happens after a clinical trial is complete? CLL expert Dr. Michael Choi explains how participants are monitored during clinical trial follow-up.
Dr. Michael Choi is a hematologist and medical oncologist at UC San Diego Moores Cancer Center. More information on Dr. Choi here.
See More from CLL Clinical Trials 201
Related Resources:
|
|
|
Transcript:
Laura Beth:
Is there follow-up that’s done after a trial concludes?
Dr. Choi:
Oh, good question. Yeah.
Yeah, trials are kind of – let me say what – yeah, when a patient goes through a trial, there can be a sense that the trial concludes, perhaps when the treatment is done or at a certain point when a response assessment is made, but oftentimes, it’s important to also continue to monitor patients after those milestones.
Certainly, for some of our drugs, the treatment continues long-term, so even after some statement has been made about a response rate, many patients remain on treatment, and it’s certainly important to see if there are any long-term side effects or any other developments after the end of that initial period.
Other treatments, the trial – the treatment may end. An example might be these trials that combine BTK inhibitors and Bcl-2 inhibitors that are typically for a year-and-a-half or so.
And certainly, for those trials, it’s definitely critical for patients to be followed as part of the trial so that we can get a good sense of how long those remissions are lasting. Also, of course, to see if there are any delayed or long-term toxicities. So, yeah, so oftentimes, being a part of a trial means being followed, being monitored for some time afterwards.
